Terns Pharmaceuticals Hits 52-Week High After Upsized Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Source: Newsfilter
Terns Pharmaceuticals Inc saw a price increase of 6.48%, reaching a 52-week high amid a significant upsized offering of 16.25 million shares priced at $40 each.
The company raised approximately $650 million, which will be allocated to research and clinical trials for its key product candidate, TERN-701. This funding is expected to enhance the company's market competitiveness and support its potential commercial launch.
The strong market confidence reflected in the offering, backed by lead underwriters Jefferies, TD Cowen, and Leerink Partners, indicates a positive outlook for Terns Pharmaceuticals as it advances its clinical programs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
